EVENTS:   Best Equity Short Ideas Conference Call 12 - Zach Shannon/Corto Capital Advisors & Craig Huber/Huber Research Partners & Thomas Beevers /Forensic Alpha & Ed Steele/Iron Blue Financials & Bill Campbell/Paragon Intel - 12 Nov 25   Will AI Deflate the World? Macro Lessons from Three Industrial Revolutions and China - Manoj Pradhan/Talking Heads Macro - 13 Nov 25     ROADSHOWS: Forest Products Sector Equity and Commodity Research With Expertise in Distressed Debt - Kevin Mason /ERA Research   •   London   12 - 14 Nov 25       Buyside to Buyside Forum and Expert Calls across TMT, Consumer, Healthcare and Fintech - Andrew Peters /Revelare Partners   •   London   17 - 19 Nov 25       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   17 - 19 Nov 25      

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

Buy Greek Banks

Financials

ResearchGreece

ResearchGreece remains bullish on Greek banks following Q1 results, citing strong economic growth, fiscal discipline and resilient asset quality that support lending, fee growth and capital generation. Higher 2026-27 RoTE estimates have led to raised price targets: NBG (€12.3), Eurobank (€3.5), Piraeus (€7.8) and Alpha (€3.1). Distribution yields range from 7.5%-10.0%, with payout ratios lifted to 70% for NBG and 60% for Eurobank. NBG, with CET1 above 19%, has the highest payout potential and deploying its €2bn in excess cash is a key catalyst. ResearchGreece favours a mix of bolt-on, fee-generating acquisitions and increased shareholder returns.

Edition: 211

- 16 May, 2025


Why are the share prices of Greek banks falling?

Financials

ResearchGreece

Recent weakness relates to investors pricing in steeper ECB rate cuts and lower rates in 2025 and 2026 than both before the central bank's Oct 17th meeting and compared to what banks have plugged in their RoTE guidance. However, ResearchGreece believes the market is overreacting to the potential earnings downgrade. If market expectations materialise, their earnings estimates are facing a 3%-7% downgrade in 2025 and 4%-6% in 2026. While a 40-100bps hit to their 2025-2026 RoTE estimates is not pleasant, it is not game changing either. ResearchGreece estimates P/TBV 2026 multiples at c.0.80x for Alpha and c.0.90x for NBG, Piraeus and Eurobank, implying 30% (NBG) to 90% (Alpha) upside from current levels.

Edition: 198

- 01 November, 2024


Eurobank (EUROB GA) Greece

Financials

ResearchGreece

Doubles its stake in Hellenic Bank to 26% to become the largest shareholder in Cyprus’ second biggest bank - valuation wise, EUROB is paying a higher multiple than when it bought its original stake (July 2021), but the truth is the outlook has improved a lot, thanks to higher rates by the ECB and HB’s enormous cash balance of €5.3bn (excl. TLTRO) equal to 27% of its total assets. ResearchGreece expects HB to revise its RoTE target >10% from c.7% previously. Using 12% CoE they find the fair P/TBV to be closer to 1.0x, which implies EUROB bought the stake at a 50% discount to fair value.

Edition: 150

- 09 December, 2022


Bank of Cyprus (BOCH CY) Cyprus

Financials

ResearchGreece

Not for turning - Board rejects Lone Star’s latest €1.51 per share offer. What should shareholders do? If you believe BoC’s RoTE will not exceed 5% by 2024 you are better off selling at any price close to €1.50. However, ResearchGreece’s base case scenario is that BoC’s RoTE will reach 7.5% in 2024 and rise to 8.3% in 2025 (both of which are below management guidance) and calculates the equity is worth €2.08-€2.19 per share (60%-70% upside). Sees no reason for the bank to trade below the average 0.43x P/TBV 2023E of its Greek peers or even below the 0.50x-0.54x of best NPE/CET1 positioned Eurobank and National Bank of Greece.

Edition: 143

- 02 September, 2022